期刊
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
卷 23, 期 1-2, 页码 157-160出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/21678421.2021.1927103
关键词
Melatonin; antioxidant; neuroinflammation; alternative therapy; clinical trials; nutrition; survival
资金
- Amyotrophic Lateral Sclerosis Association
Melatonin, reviewed as an alternative treatment for ALS, shows some positive pre-clinical studies and anecdotal evidence of potential benefits, but lacks large-scale clinical trials to support its use as a primary treatment option at this time.
ALSUntangled reviews alternative and off-label treatments for people with amyotrophic lateral sclerosis (ALS). Here we review melatonin. We show that it has plausible mechanisms, some positive (and some negative) pre-clinical studies, two cases in which cocktails of supplements including melatonin were associated with recovery of lost motor function, and a very small, flawed retrospective study suggesting that patients in the PRO-ACT database who reported taking melatonin progressed more slowly and lived longer compared to those who were not taking it. Melatonin appears safe, but an optimal dose and route of administration for ALS have not been determined. Based on all this, we support a pilot trial of melatonin in people with ALS but we cannot yet recommend it as a treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据